K. Stolze et al. / Bioorg. Med. Chem. 15 (2007) 2827–2836
2835
5.2.7. Synthesis of the N-oxides. Synthesis of the nitrones
was performed according to the procedure described re-
cently for the synthesis of EMPO derivatives.1–3,21 To a
concentrated solution of 25 mmol of the respective ethyl
2-alkyl-4-formyl-2-nitroalkanoate in H2O/CH3OH (v/
v = 6:4), an aqueous solution of ammonium chloride
(1.87 g in 8 ml of water) was added. While zinc dust
(8.5 g, 130 mmol) was slowly added within 30 min, the
mixture was carefully kept at room temperature. The
mixture was stirred for 4.5 h at room temperature, the
white precipitate and the remaining zinc powder were re-
moved by filtration, and the residue was washed five
times with methanol (30 ml). The liquid phase was con-
centrated to about 10 ml, saturated with borax, and ex-
tracted 4 times with 60 ml CH2Cl2. The organic phase
was dried with Na2SO4, filtered, and concentrated.
Careful purification by column chromatography on sil-
ica gel with a petroleum ether/ethanol gradient allowed
the separation from the majority of side products and
provided the product as a yellow oil or yellow needles.
Additional purification was done immediately before
the EPR experiments on a 1 ml solid phase extraction
column using a Chromabond C-18 100 mg column ob-
5.2.8.3. trans-5,3-EEMPO. 1H NMR: 00.97 (t, 3H,
5bCH3), 1.20 (d, 3H, 3aCH3), 1.29 (t, 3H, 2 CH3), 1.76
(dd, 1H, CHB, trans to ester, cis to Et and Me), 1.92–
4
2.09 (m, 1H, 5aCH2A), 2.18–2.36 (m, 1H, 5aCH2B), 2.62
4
(dd, 1H, CHA, cis to ester, trans0 to Et and Me), 3.17
(m, 1H, 3CH), 4.26 (m, 2H, 1 CH2), 6.91 (d, 1H,
3J = 3.6 Hz, 2CH). 13C NMR: 7.2 (5bCH3), 13.9
0
(2 CH3), 18.4 (3aCH3), 25.8 (5aCH2), 33.7 (3CH), 36.4
0
(4CH2), 62.0 (OA1 CH2); 83.1 (5C); 140.4 (N@2CH),
170.1 (COO).
5.2.8.4. cis-5,3-EEMPO. 1H NMR: 0.95 (t, 3H,
0
5bCH3), 1.25 (d, 3H, 3aCH3), 1.31 (t, 3H, 2 CH3), 1.92–
4
2.09 (m, 1H, 5aCH2A), 2.07 (m, 1H, CHB, cis to ester),
2.18–2.36 (m, 1H, 5aCH2B), 2.49 (dd, 1H, 04CHA, trans to
3
ester), 3.04 (m, 1H, CH), 4.26 (m, 2H, 1 CH2), 6.90 (d,
1H, 3J = 2.7 Hz, 2CH). 13C NMR: 7.0 (5bCH3), 13.8
0
(2 CH3), 19.1 (3aCH3), 25.2 (5aCH2), 33.1 (3CH), 36.1
0
(4CH2), 62.0 (OA1 CH2); 83.0 (5C); 139.8 (N@2CH),
169.8 (COO).
5.2.8.5. trans-4,5-EEMPO. 1H NMR: 0.93 (d, 3H,
0
4bCH3), 1.31 (t, 3H, 2 CH3), 1.34–1.45 (m, 1H, 4aCH2A),
1.55–1.66 (m, 1H, 4aCH2B), 1.61 (s, 3H, 5aCH3), 2.30–
tained from Macherey-Nagel (Duren, Germany). The
¨
purity of the obtained products was assessed by TLC
and UV spectroscopy. Final identification of the purified
3
2.48 (m, 1H, CH2B), 2.72–2.81 (m, 1H, 4CH), 2.83–
0
3
2.94 (m, 1H, CH2A), 4.27 (m, 2H, 1 CH2), 7.05 (t, 1H,
1
products was performed by H NMR, 13C NMR, ESI
3J = 2.3 Hz, 2CH). 13C NMR: 11.6 (4bCH3), 13.9
0
Q-TOF HR-MS (Table 1), and IR spectroscopy (Table
2).
(2 CH3), 14.8 (5aCH3), 22.7 (4aCH2), 32.7 (3CH2), 44.2
0
(4CH), 62.3 (OA1 CH2); 82.1 (5C); 136.1 (N@2CH),
170.0 (COO).
5.2.8. NMR. 1H NMR spectra were recorded at
300.13 MHz, 13C NMR spectra at 75.47 MHz with
CDCl3 as the solvent and TMS as the internal stan-
dard - if not stated otherwise. Data are given in
ppm units. 13C peaks were assigned by means of
HMQC and HMBC spectra. The numbering of car-
bons follows the conventions in spin trap studies, it
should be noted that the numbering of the heterocyclic
atoms runs opposite to conventional heterocycle
nomenclature (C-2 is the double-bonded carbon, while
C-5 is the quaternary C carrying the ethoxycarbonyl
group).
5.2.8.6. cis-4,5-EEMPO. 1H NMR: 0.97 (d, 3H,
0
4bCH3), 1.31 (t, 3H, 2 CH3), 1.34–1.45 (m, 1H, 4aCH2A),
1.55–1.66 (m, 1H, 4aCH2B), 1.70 (s, 3H, 5aCH3), 2.22–
4
2.27 (m, 1H, CH), 2.32–2.43 (m, 1H, 3CH2B), 2.80–
0
3
2.90 (m, 1H, CH2A), 4.27 (m, 2H, 1 CH2), 7.22 (t, 1H,
3J = 2.6 Hz, 2CH). 13C NMR: 11.9 (4bCH3), 14.1
0
(2 CH3), 20.5 (5aCH3), 23.3 (4aCH2), 32.4 (3CH2), 47.8
0
(4CH), 62.1 (OA1 CH2); 81.9 (5C); 138.3 (N@2CH),
168.1 (COO).
5.2.8.7. trans-5,4-EEMPO. 1H NMR: 1.02 (d, 3H,
0
5bCH3), 1.18 (d, 3H, 4aCH3), 1.31 (t, 3H, 2 bCH3),
1.91–2.11 (m, 1H, 5aCH2A), 2.13–2.28 (m, 1H,
1
5.2.8.1. trans-3,5-EEMPO. H NMR: 0.85 (t, 3H,
0
3bCH3), 1.17 (m, 3H, 2 CH3), 1.28–1.54 (m, 2H,
3aCH2), 1.59 (s, 3H, 5aCH3), 1.62 (dd, 1H, 4CHB,
trans to ester, cis to Et and Me), 2.57 (dd, 1H,
5aCH2B), 2.32 (m, 1H, CH2B), 2.91 (m, 1H, CH2A),
3
3
0
2.96 (m, 1H, 4CH), 4.27 (m, 2H, 1 CH2), 7.10 (t,
1H, 3J = 2.3 Hz, 2CH). 13C NMR: 8.6 (5bCH3), 13.9
0
4CHA, cis to ester, trans to Et and Me), 2.86 (m,
(2 CH3), 14.3 (4aCH3), 22.6 (5aCH2), 35.1 (3CH2),
0
0
1H, 3CH), 4.12 (m, 2H, 1 CH2), 6.82 (d, 1H,
37.0 (4CH), 61.9 (OA1 CH2); 84.8 (5C); 136.0
(N@2CH), 169.7 (COO).
3J = 2.0 Hz, 2CH). 13C NMR: 11.4 (3bCH3), 13.9
0
(2 CH3), 21.7 (5aCH3), 26.5 (3aCH2), 39.2 (4CH2),
0
40.4 (3CH), 62.2 (OA1 CH2); 79.4 (5C); 139.0
(N@2CH), 170.1 (COO).
5.2.8.8. cis-5,4-EEMPO. 0.980 (d, 3H, 5bCH3), 1.09
(d, 3H, 4aCH3), 1.31 (t, 3H, 2 bCH3), 1.91–2.11 (m,
1H, 5aCH2A), 2.13–2.28 (m, 1H, 5aCH2B), 2.41 (m,
1H, 3CH2B), 2.73 (m, 1H, 0 4CH), 2.81 (m, 1H,
3CH2A), 4.27 (m, 2H, 1 CH2), 7.18 (t, 1H,
5.2.8.2. cis-3,5-EEMPO. 1H NMR: 0.85 (t, 3H,
0
3bCH3), 1.17 (m, 3H, 2 CH3), 1.28–1.54 (m, 2H,
3aCH2), 1.58 (s, 3H, 5aCH3), 2.11 (m, 1H, 4CHB, cis
3J = 2.3 Hz, 2CH). 13C NMR: 7.0 (5bCH3), 14.0
0
to ester), 2.20 (m, 1H, 4CHB, trans to ester), 2.78
(2 CH3), 15.2 (4aCH3), 23.07 (5aCH2), 34.21 (3CH2),
34.25 (4CH), 61.8 (OA1 CH2); 85.4 (5C); 138.0
(N@2CH), 168.2 (COO).
0
(m, 1H, 3CH), 4.12 (m, 2H, 1 CH2), 6.78 (d, 1H,
3J = 2.2 Hz, 2CH). 13C NMR: 11.6 (3bCH3), 14.0
0
(2 CH3), 21.4 (5aCH3), 26.4 (3a CH2), 38.1 (4CH2),
0
40.2 (3CH), 62.2 (OA1 CH2); 79.4 (5C); 138.0
(N@2CH), 169.9 (COO).
5.2.9. Preparation of lipid hydroperoxides. Linoleic acid
hydroperoxide was synthesized according to O’Brien.24